Bulbar Urethral Strictures 101 - A Review Of The Guidelines And Basic Management Options by American Urological Association

Learning Objective: At the conclusion of this continuing medical education activity, the participant will be able to select different strategies for ureteroscopic renal stone surgery, determine how laser parameter selection can improve lithotripsy efficiency and identify the important safety considerations to optimize patient outcomes.

At the conclusion of this activity, participants will be able to:

1. Explain the sequencing of novel therapies and be able to identify patient progression of disease.

2. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

CME Available: auau.auanet.org/node/29811

At the conclusion of this activity, participants will be able to:

1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.

2. Explain best practices in MIBC and NMIBC patient selection for various treatment options.

3. Facilitate discussions with patients and caregivers regarding their treatment options.

This educational series is supported by independent educational grants from:

• Astellas

• AstraZeneca

• Bristol Myers Squibb

• Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

• Merck

• Pfizer, Inc

• Sanofi Genzyme

• UroGen Pharma, Inc.

CME Available: auau.auanet.org/node/29836

Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020)

Presented by Leonard Gomella, MD and Joshua Lang, MD

This educational activity is supported by independent educational grants from:

AbbVie

Astellas

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc.

CME Available: https://auau.auanet.org/node/30124

Presented by Kelly Stratton, MD and Alicia Morgans, MD

This educational activity is supported by independent educational grants from:

AbbVie

Astellas

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc.

CME Available: https://auau.auanet.org/node/30123

Case-Based Discussion: BCR and mHSPC and M0 CRPC

Presented by Stephen Boorjian, MD and Michael Cookson, MD

This educational activity is supported by independent educational grants from:

AbbVie

Astellas

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc.

CME Available: https://auau.auanet.org/node/30122

At the conclusion of this activity, participants will be able to:

1. Identify the role of genetic testing in men with advanced, metastatic and CRPC.

2. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

3. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.

4. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

At the conclusion of this activity, participants will be able to:

1. Examine racial and geographic disparities in in prostate cancer and prostate cancer care.

2. Identify important causes for disparities as well as possible remedies to address these causes.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

At the conclusion of this activity, participants will be able to:

1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment.

2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

CME Available: https://auau.auanet.org/node/29841